View Older Stories View More Recent Stories

Mar 12, 2018 09:10AM Gilead (GILD) Says Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Mar 12, 2018 09:00AM Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Mar 5, 2018 04:01PM Gilead Sciences (GILD) Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy From Boosted Protease Inhibitor-Based Regimen
Mar 5, 2018 04:00PM Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted El
Mar 5, 2018 12:08PM Gilead (GILD) Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy from Regimen Containing Abacavir, Dolutegravir and Lamivudine
Mar 5, 2018 12:07PM Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lami
Mar 5, 2018 05:48AM Gilead Sciences (GILD) Reports Preclinical Data on Study Evaluating Combination of GS-9620 and PGT121
Mar 4, 2018 04:19PM Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed
Feb 22, 2018 05:04PM Gilead Sciences (GILD) Says James Meyers, EVP, Commercial Operations, Will Retire
Feb 22, 2018 05:00PM Gilead Sciences Announces Senior Management Change
Feb 8, 2018 04:01PM Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
Feb 7, 2018 02:24PM Gilead Sciences (GILD) Announces FDA Approval for Biktarvy for Treatment of HIV-1 Infection
Feb 7, 2018 02:22PM U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Feb 6, 2018 04:02PM Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend
Feb 1, 2018 04:05PM Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors
Jan 23, 2018 04:01PM Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
Jan 18, 2018 08:32AM Gilead's (GILD) Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta and Pfizer's (PFE) Utomilumab in Large B-Cell Lymphoma
Jan 18, 2018 08:30AM Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Dec 21, 2017 04:01PM Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8
Dec 14, 2017 04:31PM Gilead Sciences (GILD) Says John C. Martin to Transition From Executive Chairman to Chairman
Dec 14, 2017 04:30PM Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
Dec 12, 2017 05:56AM Gilead Sciences (GILD) Company, Kite, Reports Data From ZUMA-3 Study of KTE-C19
Dec 11, 2017 07:30PM Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Dec 11, 2017 06:08AM Gilead Sciences' (GILD) Kite LT Pivotal ZUMA-1 Study of Yescarta Shows 42% of Patients Remained in Response, Including 40% in Complete Remission
Dec 10, 2017 10:30AM Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Dec 7, 2017 05:01PM Gilead Sciences (GILD) and Kite to Acquire Cell Design Labs for up to $567M
Dec 7, 2017 05:00PM Gilead Sciences and Kite to Acquire Cell Design Labs
Dec 4, 2017 06:30AM Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
Nov 22, 2017 09:00AM Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6
Oct 26, 2017 04:02PM Gilead Sciences Announces Fourth Quarter 2017 Dividend
Oct 24, 2017 04:01PM Gilead Sciences to Present at the Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7
Oct 24, 2017 08:37AM Gilead Sciences (GILD) Announces Phase 2 Results for GS-0976 in NASH
Oct 24, 2017 08:36AM Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)
Oct 20, 2017 08:05AM Gilead (GILD) Says Presentations Show High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy in HBV Patients Switched from Viread
Oct 20, 2017 08:03AM Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched fr
Oct 19, 2017 06:37AM BioLife Solutions (BLFS) Customer Kite Pharma Granted FDA Approval for Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy
Oct 18, 2017 05:46PM Gilead Sciences (GILD) Announces Kite's Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of Adult Patients With R/R Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Oct 18, 2017 05:43PM Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More L
Oct 17, 2017 08:30AM Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
Oct 16, 2017 08:00AM Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
Oct 12, 2017 04:01PM Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017
Oct 4, 2017 08:02AM Gilead Sciences (GILD) Presents Results From Phase 3 Study Evaluating Patients Who Switched to Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
Oct 4, 2017 08:00AM Loncar Cancer Immunotherapy Index Announces Merger Replacements
Oct 4, 2017 08:00AM Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhi
Oct 4, 2017 05:43AM Gilead Sciences (GILD) Reports New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Oct 4, 2017 03:01AM Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Oct 3, 2017 08:45AM Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
Oct 3, 2017 08:01AM Gilead Sciences (GILD) Completes Tender Offer for Shares of Kite Pharma (KITE)
Oct 3, 2017 08:00AM Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
Sep 27, 2017 04:31PM Gilead Sciences (GILD) Says COO Kevin Young to Retire
View More Recent Stories View Older Stories